ELVN | Ticker Profile - Titan Protect

ELVN

Enliven Therapeutics, Inc.

Healthcare · Biotechnology · NMS

$34.71

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.5B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-17.37

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-26.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$57.50

+66% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

https://www.enliventherapeutics.com

Country: United States Employees: 61 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.788

Good returns relative to risk taken

Kelly Fraction

0.0669

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.773

Acceptable balance between returns and drawdown risk

Annual Return

38.3%

Historical annualised return based on price data

Max Drawdown

-49.5%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.45

Very low correlation to market moves

52W High

$48.53

28% below the year high

52W Low

$14.79

135% above the year low

Avg Volume

1,093,904

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

13.3%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.64

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.07

Conservative use of debt — low financial risk

Current Ratio

40.32

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

39.38

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-46,080,500

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-98,777,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$80.00

Target Median

$57.50

Target Low

$45.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go